Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 7 (2010), Issue 4 (April)

  1. Effect of dutasteride on the risk of prostate cancer.
    N Engl J Med, 362(13): 1192-202. [Abstract] [Full-text]
  2. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene, 29(13): 1883-96. [Abstract] [Full-text]
  3. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
    Prostate, 70(6): 675-88. [Abstract] [Full-text]
  4. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
    Prostate, 70(6): 630-45. [Abstract] [Full-text]
  5. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
    Prostate, 70(6): 616-29. [Abstract] [Full-text]
  6. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.
    Prostate, 70(6): 646-53. [Abstract] [Full-text]
  7. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma.
    Prostate, 70(6): 666-74. [Abstract] [Full-text]
  8. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk.
    Prostate, 70(6): 601-7. [Abstract] [Full-text]
  9. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
    Prostate, 70(6): 591-600. [Abstract] [Full-text]
  10. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
    Prostate, 70(6): 571-83. [Abstract] [Full-text]
  11. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
    J Med Chem, 53(7): 2779-96. [Abstract] [Full-text]
  12. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Cancer Immunol Immunother, 59(6): 943-53. [Abstract] [Full-text]
  13. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.
    Clin Exp Metastasis, 27(3): 173-84. [Abstract] [Full-text]
  14. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.
    Cancer Res, 70(7): 2728-38. [Abstract] [Full-text]
  15. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.
    Cancer Res, 70(7): 2809-18. [Abstract] [Full-text]
  16. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation.
    Cancer Res, 70(7): 2829-39. [Abstract] [Full-text]
  17. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
    Cancer Res, 70(7): 2613-23. [Abstract] [Full-text]
  18. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.
    Cancer Res, 70(7): 2595-603. [Abstract] [Full-text]
  19. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.
    Cancer Res, 70(7): 2880-90. [Abstract] [Full-text]
  20. Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 353-9. [Abstract] [Full-text]
  21. Extraperitoneal approach induces postoperative inguinal hernia compared with transperitoneal approach after laparoscopic radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 349-52. [Abstract] [Full-text]
  22. Clinical safety and feasibility of a newly developed, simple algorithm for decision-making on neurovascular bundle preservation in radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 343-8. [Abstract] [Full-text]
  23. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Biochem Biophys Res Commun, 394(2): 297-302. [Abstract] [Full-text]
  24. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
    Cancer Lett, 291(2): 167-76. [Abstract] [Full-text]
  25. DNA mismatch repair and the transition to hormone independence in breast and prostate cancer.
    Cancer Lett, 291(2): 142-9. [Abstract] [Full-text]
  26. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer.
    Cancer Invest, 28(4): 424-32. [Abstract] [Full-text]
  27. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
    DNA Cell Biol, 29(4): 183-90. [Abstract] [Full-text]
  28. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy.
    Am J Clin Oncol, 33(2): 173-5. [Abstract] [Full-text]
  29. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy.
    Am J Clin Oncol, 33(2): 164-7. [Abstract] [Full-text]
  30. Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis.
    Am J Clin Oncol, 33(2): 168-72. [Abstract] [Full-text]
  31. Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
    J Pathol, 221(1): 68-76. [Abstract] [Full-text]
  32. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
    Oncogene, 29(14): 2036-46. [Abstract] [Full-text]
  33. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells.
    Biochem Biophys Res Commun, 394(3): 715-20. [Abstract] [Full-text]
  34. Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing?
    Cancer Treat Rev, 36(3): 230-4. [Abstract] [Full-text]
  35. Risk stratification of men choosing surveillance for low risk prostate cancer.
    J Urol, 183(5): 1779-85. [Abstract] [Full-text]
  36. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    J Urol, 183(5): 2054-61. [Abstract] [Full-text]
  37. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
    J Urol, 183(5): 2045-53. [Abstract] [Full-text]
  38. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
    J Urol, 183(5): 2062-9. [Abstract] [Full-text]
  39. Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
    J Urol, 183(5): 1816-21. [Abstract] [Full-text]
  40. Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors.
    J Urol, 183(5): 1808-14. [Abstract] [Full-text]
  41. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.
    J Urol, 183(5): 1822-8. [Abstract] [Full-text]
  42. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    J Urol, 183(5): 1786-91. [Abstract] [Full-text]
  43. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.
    J Urol, 183(5): 1792-6. [Abstract] [Full-text]
  44. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery.
    J Urol, 183(5): 1803-7. [Abstract] [Full-text]
  45. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
    J Urol, 183(5): 1798-802. [Abstract] [Full-text]
  46. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.
    J Urol, 183(5): 1751-6. [Abstract] [Full-text]
  47. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
    Biochem Pharmacol, 79(12): 1727-35. [Abstract] [Full-text]
  48. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.
    Cancer Cell, 17(4): 319-32. [Abstract] [Full-text]
  49. Prostate cancer: beta control your hormones.
    Cancer Cell, 17(4): 311-2. [Abstract] [Full-text]
  50. alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.
    Br J Cancer, 102(8): 1224-34. [Abstract] [Full-text]
  51. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
    Strahlenther Onkol, 186(4): 197-202. [Abstract] [Full-text]
  52. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Cancer Chemother Pharmacol, 66(1): 181-9. [Abstract] [Full-text]
  53. Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy.
    Cancer, 116(8): 1909-17. [Abstract] [Full-text]
  54. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
    Cancer, 116(8): 1887-92. [Abstract] [Full-text]
  55. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer.
    Cancer Res, 70(8): 3382-90. [Abstract] [Full-text]
  56. NKX3.1 activates cellular response to DNA damage.
    Cancer Res, 70(8): 3089-97. [Abstract] [Full-text]
  57. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.
    Cancer Res, 70(8): 3309-19. [Abstract] [Full-text]
  58. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
    Cancer Res, 70(8): 3239-48. [Abstract] [Full-text]
  59. Immunohistochemical expression of BRCA1 and lethal prostate cancer.
    Cancer Res, 70(8): 3136-9. [Abstract] [Full-text]
  60. p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells.
    Cancer Res, 70(8): 3150-8. [Abstract] [Full-text]
  61. Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy vs. 78 Gy.
    Int J Radiat Oncol Biol Phys, 77(1): 131-8. [Abstract] [Full-text]
  62. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 77(1): 139-46. [Abstract] [Full-text]
  63. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
    Int J Radiat Oncol Biol Phys, 77(1): 160-4. [Abstract] [Full-text]
  64. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 77(1): 147-52. [Abstract] [Full-text]
  65. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Int J Radiat Oncol Biol Phys, 77(1): 125-30. [Abstract] [Full-text]
  66. A prospective study of intrafraction prostate motion in the prone vs. supine position.
    Int J Radiat Oncol Biol Phys, 77(1): 165-70. [Abstract] [Full-text]
  67. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis.
    Int J Radiat Oncol Biol Phys, 77(1): 153-9. [Abstract] [Full-text]
  68. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(12): 2070-6. [Abstract] [Full-text]
  69. PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo.
    J Surg Oncol, 101(6): 513-9. [Abstract] [Full-text]
  70. A method to separate the rectum from the prostate during proton beam radiotherapy of prostate cancer patients.
    Acta Oncol, 49(4): 500-5. [Abstract] [Full-text]
  71. Variation in position and volume of organs at risk in the small pelvis.
    Acta Oncol, 49(4): 491-9. [Abstract] [Full-text]
  72. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Int J Cancer, 126(12): 2826-34. [Abstract] [Full-text]
  73. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.
    Prostate, 70(7): 735-44. [Abstract] [Full-text]
  74. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Prostate, 70(7): 718-26. [Abstract] [Full-text]
  75. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
    Prostate, 70(7): 788-96. [Abstract] [Full-text]
  76. Racial differences in prostate cancer risk remain among US servicemen with equal access to care.
    Prostate, 70(7): 727-34. [Abstract] [Full-text]
  77. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.
    Prostate, 70(7): 710-7. [Abstract] [Full-text]
  78. Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature.
    Prostate, 70(7): 701-9. [Abstract] [Full-text]
  79. Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.
    Cancer Lett, 292(2): 176-85. [Abstract] [Full-text]
  80. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
    J Natl Cancer Inst, 102(8): 522-8. [Abstract] [Full-text]
  81. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features.
    Radiology, 255(2): 485-94. [Abstract] [Full-text]
  82. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Lancet, 375(9724): 1437-46. [Abstract] [Full-text]
  83. Increased risk of high-grade prostate cancer among infertile men.
    Cancer, 116(9): 2140-7. [Abstract] [Full-text]
  84. Quality of end-of-life care in low-income, uninsured men dying of prostate cancer.
    Cancer, 116(9): 2126-31. [Abstract] [Full-text]
  85. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
    Cancer, 116(9): 2132-9. [Abstract] [Full-text]
  86. The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.
    Prostate, 70(8): 916-20. [Abstract] [Full-text]
  87. Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort.
    Prostate, 70(8): 906-15. [Abstract] [Full-text]
  88. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.
    Prostate, 70(8): 883-8. [Abstract] [Full-text]
  89. Genetic alterations and changes in expression of histone demethylases in prostate cancer.
    Prostate, 70(8): 889-98. [Abstract] [Full-text]
  90. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
    Prostate, 70(8): 875-82. [Abstract] [Full-text]
  91. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Prostate, 70(8): 866-74. [Abstract] [Full-text]
  92. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
    Prostate, 70(8): 848-55. [Abstract] [Full-text]
  93. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Prostate, 70(8): 817-24. [Abstract] [Full-text]
  94. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.
    Br J Cancer, 102(9): 1335-40. [Abstract] [Full-text]
  95. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
    Cancer Immunol Immunother, 59(7): 1001-9. [Abstract] [Full-text]
  96. Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells.
    Oncogene, 29(17): 2457-66. [Abstract] [Full-text]
  97. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.
    Oncogene, 29(17): 2477-87. [Abstract] [Full-text]
  98. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
    Cancer Res, 70(9): 3667-76. [Abstract] [Full-text]
  99. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
    Cancer Res, 70(9): 3473-82. [Abstract] [Full-text]
  100. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors.
    Cancer Res, 70(9): 3505-14. [Abstract] [Full-text]
  101. Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1.
    J Cell Physiol, 224(1): 210-7. [Abstract] [Full-text]
  102. Transcriptional regulation of Rex1 (zfp42) in normal prostate epithelial cells and prostate cancer cells.
    J Cell Physiol, 224(1): 17-27. [Abstract] [Full-text]
  103. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer.
    Aging Male, 13(2): 120-3. [Abstract] [Full-text]
  104. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
    Aging Male, 13(2): 87-92. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life

Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life